Record mula sa primary source
Decision-gradeTopline na resulta
SELLAS: Inaasahan ang topline data ng Phase 2 SLS009 para sa AML sa Q4 2026
Inihayag ng kumpanya na 28 sa 80 planadong pasyente ang naka-enroll sa Phase 2 trial ng SLS009 sa newly diagnosed first-line AML at inaasahang lalabas ang topline data sa Q4 2026. Ito ang susunod na clinical readout milestone para sa CDK9 inhibitor program.
Mahahalagang fact
- Na-file
- Ago 11, 2026, 08:07 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Neutral
- Kumpanya
SLSSELLAS Life Sciences- Asset
- SLS009
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- Laki ng pagsubok
- 80
- patients na naka-enroll
- 28
Sipi mula sa source
EX-99.1 2 sls-202608118xkexhibit991.htm EX-99.1 Document Exhibit 99.1 SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - – 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 – – Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, NY, August 11, 2026 -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceuti